| Product | Strength | Indication | GMP | Business Model |
|---|
| Beraprost Sodium Tablets | 40μg | To manage conditions related to poor blood flow, such as pulmonary arterial hypertension, Raynaud’s phenomenon, and peripheral artery disease | CN | Dist |
| Dalteparin Sodium Injection | 0.2ml:5000IU; 0.3ml:7500IU | For the treatment of acute deep vein thrombosis; To prevent coagulation in the extracorporeal circulation system during hemodialysis and hemofiltration in patients with acute renal failure or chronic renal insufficiency; For the treatment of unstable coronary artery disease, such as unstable angina and non-Q wave myocardial infarction; To prevent thrombus formation associated with surgery. | CN | Dist |
| Enoxaparin Sodium Injection | 0.4ml:4000AXaIU; 0.6ml:6000 AXaIU | For the treatment of established deep vein thrombosis, with or without pulmonary embolism, in patients with non-severe clinical symptoms, excluding those with pulmonary embolism requiring surgical or thrombolytic therapy. For the treatment of unstable angina and non-Q wave myocardial infarction, in combination with aspirin. To prevent thrombus formation in the extracorporeal circulation during hemodialysis. For the treatment of acute ST-segment elevation myocardial infarction, in combination with thrombolytic agents or concurrently with percutaneous coronary intervention (PCI).** | CN | Dist |
| Enoxaparin Sodium Injection | 0.2ml:2000AXaIU; 0.4ml:4000AXaIU; 0.6ml:6000AXaIU; 0.8ml:8000AXaIU; 1.0ml:10000AXaIU | Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery. Prevention of thrombus formation in extra corporeal circulation during haemodialysis. Acute coronary syndrome | EU, CN, US | Dist |
| Fondaparinux Sodium Injection | 0.5ml: 2.5mg | For the prevention of venous thromboembolic events in patients undergoing major orthopedic surgery of the lower limbs, such as hip fractures, major knee surgeries, or hip replacements. For the treatment of patients with unstable angina or non-ST-segment elevation myocardial infarction (UA/NSTEMI) who are not candidates for urgent (<120 minutes) invasive treatment (PCI). For the treatment of patients with ST-segment elevation myocardial infarction who are undergoing thrombolysis or who do not initially receive other forms of reperfusion therapy. | CN | Dist, TT |
| Heparin Sodium Injection | 2.0ml/12500IU; 5.0ml/5000IU; 5.0ml/25000IU | For the prevention and treatment of deep vein thrombosis, and can also be used to prevent blood clot formation during hemodialysis | CN | Dist |
| Human Albumin | 5g/vial (5%, 100mL); 5g/vial (20%, 25mL); 10g/vial (20%, 50mL); 12.5g/vial (25%, 50mL) | Shock due to loss of blood or burns; increased cranial pressure due to cerebral oedema and injury; oedema or ascites due to liver cirrhosis and kidney disease; Prevention and treatment of hypoproteinemia; neonatal hyperbilirubinemia; cardiopulmonary bypass, adjunctive treatment of burns, adjunctive treatment of haemodialysis and adult respiratory distress syndrome | CN | Dist |
| Human Coagulation Factor VIII | 200IU | Correction on coagulation dysfunction caused by lack of human coagulation factor VIII | CN | Dist |
| Human Fibrinogen | 0.5g/vial | Congenital fibrinogen reduction or deficiency; acquired fibrinogenopenia disease | CN | Dist |
| Human Prothrombin Complex | 400IU factor IX, 400IU factor II, 200IU factor VIII, 400IU factor X | Congenital and acquired deficiency of coagulation factor II, VII, IX and X. | CN | Dist |
| Low Molecular Weight Heparin Sodium Injection | 0.2ml:2050AXaIU; 0.4ml:4100AXaIU | For the prevention and treatment of deep vein thrombosis, and can also be used to prevent blood clot formation during hemodialysis | CN | Dist |
| Mecobalamin Tablets | 0.5mg | Peripheral neuropathy; diabetic neuropathy | CN | Dist, TT |
| Nadroparin Calcium Injection | 0.4ml:4100AXaIU; 0.6ml:6150AXaIU | In surgical procedures, it is used for the prevention of venous thromboembolic diseases in situations with moderate or high risk of venous thrombosis formation; For the treatment of established deep vein thrombosis; Used in combination with aspirin for the treatment of unstable angina and acute phase of non-Q wave myocardial infarction; To prevent blood clot formation in the extracorporeal circulation during hemodialysis. | CN | Dist |
| Recombinant Human Erythropoietin Injection | 4000IU/1ml | Anemia caused by CKD | CN | Dist, TT |
| Reteplase | 18mg/10ml | Thrombocytopenia caused by radiotherapy or chemotherapy | CN | Dist, TT |
| Tenecteplase | 1.0*10^7 IU/16mg | Acute ischemic stroke; Acute myocardial infarction | CN | Dist |
